Beta therapy with 90strontium as single modality therapy for canine squamous cell carcinoma in third eyelid

3Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

Abstract

The purpose was to evaluate the effectiveness of beta-radiation with strontium-90 as single modality treatment of canine third eyelid squamous cell carcinoma (SCC). Nine dogs diagnosed with third eyelid SCC were treated with strontium-90. Radiation therapy was administered in four fractions of 100cGy per site every four days and at a depth of 0.2cm (Strontium-90 build’ up) in each fraction. Radiation with beta therapy was well tolerated in all animals with no occurrence of radiation induced cataracts. In all cases, there were increased signs of conjunctival inflammation around the mass, which subsided with topical anti-inflammatory. Two dogs required surgical treatment for local tumor recurrence at 150 days and 352 days. In the remaining seven cases, disease free interval ranged from 1239 days to 2555 days. Beta therapy using 90Sr may be a valid alternative for the treatment of third eyelid SCC in dogs.

Cite

CITATION STYLE

APA

de Andrade, A. L., Fernandes, M. A. R., Sakamoto, S. S., & Luvizotto, M. C. R. (2015). Beta therapy with 90strontium as single modality therapy for canine squamous cell carcinoma in third eyelid. Ciencia Rural, 45(6), 1066–1072. https://doi.org/10.1590/0103-8478cr20140918

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free